Doc Akers-White Faces Secret Federal Ruling: What Happened?
Published Date: 12/4/2025
Notice
Summary
Dr. Latania Akers-White from Virginia lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration as of June 30, 2025. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Akers-White
The DEA revoked Latania Akers-White, M.D.'s Certificate of Registration No. FA2343630 and denied any pending applications to renew, modify, or add registrations in Virginia. The registration revocation order is effective January 5, 2026; her DEA registration had expired on June 30, 2025 and her Virginia medical license was suspended on or about July 11, 2024.
DEA Authority When State License Suspended
Under 21 U.S.C. 824(a)(3) and related provisions, the DEA may suspend or revoke a practitioner's registration when the practitioner's State license or registration has been suspended or revoked so that the practitioner is no longer authorized to handle controlled substances in that State. The agency states that a practitioner must have state authority to dispense controlled substances in the State where they practice to be eligible to maintain a DEA registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-21884 — Agency Information Collection Activities; Submission of Proposed Information Collection; Online Training Request Form for OMB Review
The Access Board is asking for approval to start a new online form that lets people and local governments easily request training. This change makes it simpler to get help and doesn’t cost anyone extra. You can share your thoughts on this plan until January 5, 2026.
Next: 2025-21886 — Endangered and Threatened Species; Issuance of Enhancement of Survival and Incidental Take Permits for Safe Harbor Agreements, Candidate Conservation Agreements, Conservation Plans, and Recovery Activities; January 1, 2024, Through December 31, 2024
The U.S. Fish and Wildlife Service is sharing a list of permits issued in 2024 that allow certain activities affecting endangered and threatened species. These permits help people and groups safely work on conservation projects, recovery efforts, and habitat plans without breaking the law. This update keeps everyone informed about who’s involved, what’s allowed, and when these permits apply throughout the year.